Cargando…

Identification of Enzalutamide Resistance-Related circRNA-miRNA-mRNA Regulatory Networks in Patients with Prostate Cancer

PURPOSE: This study aimed to identify enzalutamide resistant-related (EnzR-related) circRNAs and to characterize and validate circRNA-miRNA-mRNA ceRNA regulatory network and corresponding prognostic signature of prostate cancer patients. METHODS: We obtained circRNA expression microarray from the Ge...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, JunJie, Sun, Si, Mao, WeiPu, Xu, Bin, Chen, Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8232970/
https://www.ncbi.nlm.nih.gov/pubmed/34188491
http://dx.doi.org/10.2147/OTT.S309917
_version_ 1783713747052789760
author Yu, JunJie
Sun, Si
Mao, WeiPu
Xu, Bin
Chen, Ming
author_facet Yu, JunJie
Sun, Si
Mao, WeiPu
Xu, Bin
Chen, Ming
author_sort Yu, JunJie
collection PubMed
description PURPOSE: This study aimed to identify enzalutamide resistant-related (EnzR-related) circRNAs and to characterize and validate circRNA-miRNA-mRNA ceRNA regulatory network and corresponding prognostic signature of prostate cancer patients. METHODS: We obtained circRNA expression microarray from the Gene Expression Omnibus (GEO) database and performed differential expression analysis to identify EnzR-related circRNAs using the limma package. The miRNA and mRNA expression profiling were downloaded and performed differential expression analysis, then overlapped with predicted candidates. Next, we established circRNA-miRNA-mRNA ceRNA network and PPI network utilized Cytoscape software and STRING database, respectively. In addition, univariate and Lasso Cox regression analyses were applied to generate a prognostic signature. Receiver operating characteristic (ROC) curves and Kaplan–Meier analysis were used to evaluate the reliability and sensitivity of the signature. Ultimately, we chose hsa_circ_0047641 to validate the feasibility of the EnzR-related ceRNA regulatory pathway using qRT-PCR, CCK8 and Transwell assays. RESULTS: We identified 13 EnzR-related circRNAs and constructed a ceRNA regulatory network that contained two downregulated circRNAs (has-circ-00000919 and has-circ-0000036) and two upregulated circRNAs (has-circ-0047641 and has-circ-0068697), and their sponged 6 miRNAs and 167 targeted mRNAs. Subsequently, these targeted mRNAs were performed to implement PPI analysis and to identify 10 Hub genes. Functional enrichment analysis provided new ways to seek potential biological functions. Besides, we established a prognostic signature of PCa patients based on 8 prognostic-associated mRNAs. We confirmed that the survival rates of PCa patients with high-risk subgroup were slightly lower than those with low-risk subgroup in the TCGA dataset (p<0.001), and ROC curves revealed that the AUC value for prognostic signature was 0.816. Finally, the functional analysis suggested that knockdown of hsa_circ_0047641 could inhibit the progression of PCa and could reverse Enz-resistance in vitro. CONCLUSION: We identified 13 EnzR-related circRNAs, and constructed and confirmed that EnzR-related circRNA-miRNA-mRNA ceRNA network and corresponding prognostic signature could be a useful prognostic biomarker and therapeutic target.
format Online
Article
Text
id pubmed-8232970
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-82329702021-06-28 Identification of Enzalutamide Resistance-Related circRNA-miRNA-mRNA Regulatory Networks in Patients with Prostate Cancer Yu, JunJie Sun, Si Mao, WeiPu Xu, Bin Chen, Ming Onco Targets Ther Original Research PURPOSE: This study aimed to identify enzalutamide resistant-related (EnzR-related) circRNAs and to characterize and validate circRNA-miRNA-mRNA ceRNA regulatory network and corresponding prognostic signature of prostate cancer patients. METHODS: We obtained circRNA expression microarray from the Gene Expression Omnibus (GEO) database and performed differential expression analysis to identify EnzR-related circRNAs using the limma package. The miRNA and mRNA expression profiling were downloaded and performed differential expression analysis, then overlapped with predicted candidates. Next, we established circRNA-miRNA-mRNA ceRNA network and PPI network utilized Cytoscape software and STRING database, respectively. In addition, univariate and Lasso Cox regression analyses were applied to generate a prognostic signature. Receiver operating characteristic (ROC) curves and Kaplan–Meier analysis were used to evaluate the reliability and sensitivity of the signature. Ultimately, we chose hsa_circ_0047641 to validate the feasibility of the EnzR-related ceRNA regulatory pathway using qRT-PCR, CCK8 and Transwell assays. RESULTS: We identified 13 EnzR-related circRNAs and constructed a ceRNA regulatory network that contained two downregulated circRNAs (has-circ-00000919 and has-circ-0000036) and two upregulated circRNAs (has-circ-0047641 and has-circ-0068697), and their sponged 6 miRNAs and 167 targeted mRNAs. Subsequently, these targeted mRNAs were performed to implement PPI analysis and to identify 10 Hub genes. Functional enrichment analysis provided new ways to seek potential biological functions. Besides, we established a prognostic signature of PCa patients based on 8 prognostic-associated mRNAs. We confirmed that the survival rates of PCa patients with high-risk subgroup were slightly lower than those with low-risk subgroup in the TCGA dataset (p<0.001), and ROC curves revealed that the AUC value for prognostic signature was 0.816. Finally, the functional analysis suggested that knockdown of hsa_circ_0047641 could inhibit the progression of PCa and could reverse Enz-resistance in vitro. CONCLUSION: We identified 13 EnzR-related circRNAs, and constructed and confirmed that EnzR-related circRNA-miRNA-mRNA ceRNA network and corresponding prognostic signature could be a useful prognostic biomarker and therapeutic target. Dove 2021-06-21 /pmc/articles/PMC8232970/ /pubmed/34188491 http://dx.doi.org/10.2147/OTT.S309917 Text en © 2021 Yu et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Yu, JunJie
Sun, Si
Mao, WeiPu
Xu, Bin
Chen, Ming
Identification of Enzalutamide Resistance-Related circRNA-miRNA-mRNA Regulatory Networks in Patients with Prostate Cancer
title Identification of Enzalutamide Resistance-Related circRNA-miRNA-mRNA Regulatory Networks in Patients with Prostate Cancer
title_full Identification of Enzalutamide Resistance-Related circRNA-miRNA-mRNA Regulatory Networks in Patients with Prostate Cancer
title_fullStr Identification of Enzalutamide Resistance-Related circRNA-miRNA-mRNA Regulatory Networks in Patients with Prostate Cancer
title_full_unstemmed Identification of Enzalutamide Resistance-Related circRNA-miRNA-mRNA Regulatory Networks in Patients with Prostate Cancer
title_short Identification of Enzalutamide Resistance-Related circRNA-miRNA-mRNA Regulatory Networks in Patients with Prostate Cancer
title_sort identification of enzalutamide resistance-related circrna-mirna-mrna regulatory networks in patients with prostate cancer
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8232970/
https://www.ncbi.nlm.nih.gov/pubmed/34188491
http://dx.doi.org/10.2147/OTT.S309917
work_keys_str_mv AT yujunjie identificationofenzalutamideresistancerelatedcircrnamirnamrnaregulatorynetworksinpatientswithprostatecancer
AT sunsi identificationofenzalutamideresistancerelatedcircrnamirnamrnaregulatorynetworksinpatientswithprostatecancer
AT maoweipu identificationofenzalutamideresistancerelatedcircrnamirnamrnaregulatorynetworksinpatientswithprostatecancer
AT xubin identificationofenzalutamideresistancerelatedcircrnamirnamrnaregulatorynetworksinpatientswithprostatecancer
AT chenming identificationofenzalutamideresistancerelatedcircrnamirnamrnaregulatorynetworksinpatientswithprostatecancer